Cover Image
市場調查報告書

Tegafur/gimeracil/oteracil的中國市場

Investigation Report on China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332307
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Tegafur/gimeracil/oteracil的中國市場 Investigation Report on China Tegafur, Gimeracil and Oteracil (Tegafur/gimeracil/oteracil) Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 30 Pages
簡介

Tegafur/gimeracil/oteracil是Fluorouracil衍生物的一種,是口服的抗癌生技藥品。由於歷經數年的臨床應用,該藥被証實為安全性高且有效的抗癌藥。Tegafur/gimeracil/oteracil自打入中國市場以來其銷售量急速擴大,2009年不到2000萬人民幣的銷售量到2014年已達7億700萬人民幣的規模。

本報告提供中國的Tegafur/gimeracil/oteracil市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 Tegafur/gimeracil/oteracil的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國Tegafur/gimeracil/oteracil的市場簡介

  • Tegafur/gimeracil/oteracil的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國Tegafur/gimeracil/oteracil銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國Tegafur/gimeracil/oteracil的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國Tegafur/gimeracil/oteracil的劑型的相關調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的Tegafur/gimeracil/oteracil的標準價格

  • Qilu Pharmaceutical Co., Ltd
  • 大鵬藥品工業
  • Jiangsu Hengrui Medicine Co., Ltd
  • Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation

第7章 中國市場中Tegafur/gimeracil/oteracil的主要製藥公司

  • Qilu Pharmaceutical Co., Ltd
  • Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation
  • Jiangsu Hengrui Medicine Co., Ltd
  • 大鵬藥品工業

第8章 中國Tegafur/gimeracil/oteracil的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506200

Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti-cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999, it was approved to treat advanced gastric cancer and then such indications as head and neck neoplasm, inoperable or unresectable breast cancer, non-small cell carcinoma, colon cancer, pancreatic cancer and bile duct cancer.

Years of clinical application prove that tegafur, gimeracil and oteracil is a safe and effective anti-cancer drug. According to statistics, over 80% of advanced gastric cancer patients use tegafur, gimeracil and oteracil in chemotherapy, CR + PR reaching 44.6%.

According to CRI's statistics, tegafur, gimeracil and oteracil develops fast after entering China with annual sales rising from less than CNY 20 million in 2009 to CNY 707 million in 2014 and CAGR reaching up to 110% during the period of 2009-2014, which demonstrats a bright future. Tegafur, gimeracil and oteracil enjoys a vast demand in China. Currently, tegafur, gimeracil and oteracil in the Chinese market come from the following four companies: Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation, Qilu Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd and Jiangsu Hengrui Medicine Co., Ltd, among which Shandong New Time Pharmaceutical Co., Ltd has the largest market share of nearly 50% with sales reaching up to CNY 348 million in 2014.

The market size of tegafur, gimeracil and oteracil in China is expected to keep growing.

Readers can get at least the following information through this report:

  • market share of manufacturers of tegafur, gimeracil and oteracil in Chinese market
  • price of tegafur, gimeracil and oteracil in Chinese market
  • major manufacturers of tegafur, gimeracil and oteracil in China
  • share of different dosage forms of tegafur, gimeracil and oteracil in Chinese market
  • market outlook of tegafur, gimeracil and oteracil in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antitumor drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Tegafur, Gimeracil and Oteracil

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Tegafur, Gimeracil and Oteracil in China

  • 2.1. Patent and Approval Status of Tegafur, Gimeracil and Oteracil in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Tegafur, Gimeracil and Oteracil in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufactures of Tegafur, Gimeracil and Oteracil in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Tegafur, Gimeracil and Oteracil in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Tegafur, Gimeracil and Oteracil in Chinese Hospitals in 2014

  • 6.1. Qilu Pharmaceutical Co., Ltd
  • 6.2. Taiho Pharmaceutical Co., Ltd
  • 6.3. Jiangsu Hengrui Medicine Co., Ltd
  • 6.4. Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation

7. Major Manufacturers of Tegafur, Gimeracil and Oteracil in the Chinese Market, 2010-2014

  • 7.1. Qilu Pharmaceutical Co., Ltd
  • 7.2. Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation
  • 7.3. Jiangsu Hengrui Medicine Co., Ltd
  • 7.4. Taiho Pharmaceutical Co., Ltd

8. Market Outlook of Tegafur, Gimeracil and Oteracil in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Approval Information of Tegafur, Gimeracil and Oteracil in China
  • Chart Sales Status of Tegafur, Gimeracil and Oteracil in China, 2010-2014
  • Chart Sales Value of Tegafur, Gimeracil and Oteracil in China, 2010-2014
  • Chart Sales Value of Tegafur, Gimeracil and Oteracil in Some Regions in China, 2010-2014
  • Chart Sales Volume of Tegafur, Gimeracil and Oteracil in China, 2010-2014
  • Chart Market Share of TOP4 Manufacturers of Tegafur, Gimeracil and Oteracil by Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Taiho (Japan) in China, 2010-2014
  • Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Jiangsu Hengrui in China, 2010-2014
  • Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Made by Shandong New Time in China, 2010-2014
  • Chart Sales Value and Market Share of Tegafur, Gimeracil and Oteracil Capsules in China, 2010-2014
  • Chart Price of Tegafur, Gimeracil and Oteracil Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Tegafur, Gimeracil and Oteracil Made by Taiho Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Tegafur, Gimeracil and Oteracil Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Tegafur, Gimeracil and Oteracil Made by Jiangsu Aosaikang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top